This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

anakinra (Kineret®)

Reference No. 3734

Publication date:

Appraisal information

anakinra (Kineret®) 100 mg/0.67 ml solution for injection

Company: Swedish Orphan Biovitrum Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 23/07/2018

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, anakinra (Kineret®) cannot be endorsed for use within NHS Wales in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease, with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs or glucocorticoids.
Statement of Advice (SOA)